Another Indian pharma plant shuts down after COVID-19 outbreak

July 16, 2020

India-based Lupin Ltd. has closed a manufacturing plant due to an outbreak of the coronavirus. 

According to the company, at least 18 employees at a site at its 11-plant campus in Ankleshwar have tested positive for the coronavirus. Lupin said that none of the other facilities at its campus have been impacted by the outbreak so far.

Lupin, which is one of the world’s largest generic drug manufacturers, produces a wide range of therapies at the Ankleshwar campus including drugs for diabetes, heart conditions, asthma and more. One of the largest markets for drugs from company is North America.

The shutdown is one of several recent manufacturing plant closures to hit India, which is now the country with the third highest number of confirmed coronavirus cases. Earlier this month, Sun Pharma was forced to temporarily close one of its Dadra facilities after more than a dozen employees tested positive.

In May, Cadila Pharmaceuticals closed a facility in Dholka for over two weeks after 30 employees tested positive for the coronavirus. 

Read the full Reuters report.